Highest-materiality recent filing
Co-Diagnostics Q2 net loss narrows to $6.3M; FDA 510(k) submitted for Flu/RSV test
Revenue $0.17M vs $0.16M YoY; net loss $6.3M ($1.46/share) vs $7.7M ($7.00) prior year.
Co-Diagnostics raises ~$2.67M via warrant exercise; issues new warrants for 3.4M shares
Gross proceeds of ~$2.67M from cash exercise of 1,702,362 existing warrants at $1.571/share.
Co-Diagnostics removes $10M cap on ATM equity offering with Maxim Group
Amendment to equity distribution agreement removes fixed $10M aggregate limit on common stock sales.
Co-Diagnostics Q1 2026 revenue $0.15M; net loss $9.1M; advances India regulatory milestones
Revenue $0.15M vs $0.05M in Q1 2025; operating loss $9.2M vs $8.6M.
Co-Diagnostics FY2025 revenue drops 85% to $0.6M; net loss $46.9M; cash burn accelerates
Revenue fell to $0.6M from $3.9M in 2024; net loss was $46.9M ($35.25/share) vs $37.6M.
Co-Diagnostics regains Nasdaq compliance; preliminary cash $11.9M as of Dec 31, 2025
Nasdaq notified Co-Diagnostics (CODX) of compliance with $1.00 bid price rule; trading resumes March 11, 2026.
Co-Diagnostics receives Nasdaq delisting notice; trading to move to OTC Pink effective Jan 14
Nasdaq Staff determined to delist CODX due to continued non-compliance with minimum bid price rule.
Co-Diagnostics files 1-for-30 reverse stock split to regain Nasdaq minimum bid price compliance
Reverse stock split ratio set at 1-for-30; effective January 2, 2026 at 12:01 a.m. ET.
Co-Diagnostics shareholders approve reverse stock split up to 1-for-30
Special meeting on Dec 5, 2025 approved amendment for reverse stock split.
Revenue $0.1M, down from $0.6M YoY; net loss $5.9M ($0.16/share) vs $9.7M ($0.32) in Q3 2024.
Co-Diagnostics prices $7.0M registered direct offering of 12.7M shares at $0.55/share
Offering consists of 12,727,272 shares of common stock or pre-funded warrants at $0.55 per share.
New ATM allows sale of up to $10M in common stock through Maxim Group at market prices; 3.0% commission.
Co-Diagnostics announces $3.8M registered direct offering of 9.62M shares at $0.40/share
Sold 9,619,000 common shares at $0.40/share in registered direct offering to institutional investors.
Co-Diagnostics gets 180-day Nasdaq extension to meet $1 minimum bid rule
Additional 180-day grace period to regain compliance expires January 5, 2026.
Co-Diagnostics Q1 revenue $0.1M; net loss $7.5M; advancing platform pipeline
Revenue of $0.1M, down from $0.5M YoY due to no grant revenue recognized in Q1 2025.
Co-Diagnostics FY2024 revenue $3.9M, net loss $37.6M; withdraws 510(k) for platform
Revenue $3.9M vs $6.8M in 2023; product revenue $0.8M, grant revenue $3.1M.
Co-Diagnostics withdraws COVID-19 test 510(k) application; to submit enhanced version
Withdrew current 510(k) application for Co-Dx PCR COVID-19 Test after FDA feedback on component shelf-life stability.
Co-Diagnostics receives Nasdaq bid price deficiency notice; 180 days to regain compliance
Notice on Jan 10, 2025: closing bid price below $1.00 for 30 consecutive business days.
Co-Diagnostics Q3 revenue $0.6M down from $2.5M; net loss $9.7M ($0.32/share)
Q3 2024 revenue $0.6M ($0.4M grant + $0.2M product) vs $2.5M prior year, down 76%.
Co-Diagnostics Q2 revenue jumps to $2.7M, net loss narrows to $7.6M, submits 510(k) for PCR platform
Revenue of $2.7M vs $0.2M in prior year, driven by milestone achievements on grants.
Co-Diagnostics files first FDA 510(k) for Co-Dx PCR Pro platform and OTC COVID-19 test
FDA receives 510(k) submission for Co-Dx PCR Pro instrument and OTC COVID-19 test.
Co-Diagnostics Q1 net loss $9.3M ($0.31/share), revenue $0.5M, down 17% YoY
Revenue $0.5M ($0.3M product, $0.2M grant) vs $0.6M in Q1 2023.
Co-Diagnostics FY2023 revenue drops 80% to $6.8M; net loss widens to $35.3M
Revenue of $6.8M, down from $34.2M in 2022, driven by decline in COVID-19 test demand.
Co-Diagnostics Q3 revenue $2.5M, net loss $6.0M; receives $9.0M Gates Foundation grant
Revenue $2.5M, down from $5.1M in prior year due to declining COVID-19 test demand.
Revenue collapse to $0.2M, Q2 net loss $8.9M vs $2.7M a year ago
Revenue $0.2M vs $5.0M in prior-year quarter as COVID test demand declined.
Co-Diagnostics Q1 revenue drops 97% to $0.6M; net loss of $5.8M vs prior-year profit
Revenue of $0.6M, down from $22.7M a year ago due to lower COVID-19 test demand.
Co-Diagnostics reports FY2022 revenue of $34.2M, down 65% YoY; net loss $0.45/share
Revenue $34.2M, down from $97.9M in 2021 due to lower COVID-19 test demand.
Co-Diagnostics Q3 revenue $5.1M (down 83% YoY); net loss $1.4M vs prior-year income $11.5M
Revenue $5.1M, down from $30.1M a year ago; operating loss $6.5M vs income $13.6M.
Co-Diagnostics Q2 2022 revenue $5.0M, down 82% YoY; net loss $2.7M
Revenue of $5.0M vs $27.4M a year ago; gross profit margin 81.8% due to sales volume inefficiencies.
Co-Diagnostics reports Q1 revenue $22.7M, net income $11.7M ($0.34 EPS); no guidance given
Q1 revenue $22.7M, record first quarter; net income $11.7M ($0.34 diluted EPS) vs $7.9M a year ago.
Co-Diagnostics reports FY2021 revenue $97.9M, EPS $1.23; guides Q1 FY2022 revenue $21-22M
Revenue $97.9M, +$23.3M YoY; net income $36.7M ($1.23 diluted EPS) vs $42.5M ($1.52) in 2020.
Co-Diagnostics acquires Idaho Molecular and Advanced Conceptions for up to 4.72M shares and warrants
Total consideration: up to 4.72M shares of CODX common stock and 465,000 warrants at $9.125 exercise price.
Co-Diagnostics reports record Q3 revenue of $30.1M, EPS $0.38, guides FY2021 revenue $96-100M
Revenue $30.1M, up 38% YoY; gross profit $26.8M (89.0% margin).
Co-Diagnostics reports Q2 revenue of $27.4M, EPS $0.33; guides Q3 revenue $23-25M
Revenue $27.4M (+13.8% YoY); net income $9.8M ($0.33 diluted EPS) vs $15.0M ($0.51) in Q2 2020.
On March 15, 2024, the Board of Directors of Co-Diagnostics, Inc. (the “Company”) appointed Richard Abbott as President.
the Company’s Board of Directors appointed Brian L. Brown, CPA, as the Company’s Corporate Secretary.
Mr. Reed L. Benson resigned as the Corporate Secretary of Co-Diagnostics, Inc.
Max materiality 0.85 · Median 0.65 · Most common event earnings